Abstract
With the introduction of new drugs such as alpha-interferon (IFN) and purine analogs, the management of hairy cell leukemia (HCL) patients has changed. However, deoxycoformycin (DCF) produced higher complete remission rates than IFN. The current study was undertaken to provide long-term data on duration of overall survival (OS) and disease-free survival (DFS) and incidence of subsequent malignancies. We retrospectively analyzed the data of patients treated with DCF (4 mg/m2/day, every 2 weeks) from 39 French centers. In 84 of 238 included patients, DCF was the first-line therapy. Pretreatment variables influencing the achievement of complete remission, DFS, and OS were identified by multivariate analysis. Two hundred and thirty-eight patients received a median of nine cycles (range, 1–19 cycles). A complete remission was obtained in 182 of 230 evaluable patients (79%) and a partial response was obtained in 38 patients, for an overall response rate of 95.6%. In the multivariate analysis hemoglobin level less than 100 g/l and leukocytes less than 2 × 109/l were parameters adversely influencing complete remission achievement. With a median follow-up of 63.5 months (range, 0.39–138.4 months), disease recurrence was observed in 34 of 220 responding patients (15%). The estimated 5-years and 10-years DFS was 88.1% and 68.8%, respectively. Hemoglobin level less than 100 g/l and leukocytes less than 2 × 109/l were the pre-treatment variables associated with a shorter DFS. The estimated 5-year and 10-year OS were 89.4% and 88.7%, respectively. Hemoglobin level less than 100 g/l, leukocytes less than 2 × 109/l, and adenopathy were significant factors of reduced survival. Hematologic toxicity was the main side-effect, followed by infection and emesis. During the period of follow-up, 18 patients developed second cancer, but the standardized incidence ratio was 0.95. Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses. Toxicity of DCF is acceptable. Subsequent malignancies do not appear to be increased with pentostatin treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bouroncle, BA. Leukemic reticuloendotheliosis (hairy cell leukemia). Blood, (1979). 53, 412–436.
Troussard, X, Maloisel, F & Flandrin, G Hairy cell leukemia. What is new forty years after the first description? Hematol Cell Ther, (1998). 40, 139–148.
Maloisel, F, Andrès, E, Troussard, X, Herbrecht, R & Dufour, P Aspects thérapeutiques de la leucémie à tricholeucocytes. Presse Med, (1999). 28, 1887–1894.
Saven, A & Piro, L Newer purine analogues for the treatment of hairy cell leukemia. N Engl J Med, (1994). 330, 691–697.
Gollard, R, Lee, TC, Piro, LD & Saven, A The optimal management of hairy cell leukemia. Drugs, (1995). 49, 921–931.
Grever, M, Kopecky, K, Foucar, MK, Head, D, Bennett, JM, Hutchison, RE, Corbett, WEN, Cassileth, PA, Habermann, T, Golomb, H, Rai, K, Eisenhauer, E, Appelbaum, F & Cheson, BD Randomized comparison of pentostatin versus inteferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol, (1995). 13, 974–982.
Cassileth, PA, Cheuvart, B, Spiers, ASD, Harrington, DP, Cumming, FJ, Neiman, RS, Bennett, JM & O’Connel, MJ Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol, (1991). 9, 243–246.
Kraut, EH, Grever, MR & Bouroncle, BA Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood, (1994). 84, 4061–4063.
Dearden, CE, Matutes, E, Hilditch, BL, Swanbury, GJ & Catowsky, D Long-term follow-up of patients with hairy cell leukemia after treatment with pentostatin or cladribine. Br J Haematol, (1999). 106, 515–519.
Montserrat, R, Cervantes, F, Beltran, JM, Zuazu, F, Nieto, LH, Rayon, C, Talavera, JG & Monserrat, E Deoxycoformycin in the treatment of patients with hairy cell leukemia. Results of a spanish collaborative study of 80 patients. Cancer, (2000). 88, 352–357.
Ribeiro, P, Bouaffia, F, Peaud, PY, Blanc, M, Salles, B, Salles, G & Coiffier, B Long-term outcome of patients with hairy cell leukemia treated pentostatin. Cancer, (1998). 85, 65–71.
Kaplan, EL & Meier, P Nonparametric estimation from incomplete observations. J Am Stat Assoc, (1958). 53, 457–481.
Cox, DR Regression models and life-tables (with discussion). J Roy Stat Soc Ser B, (1972). 34, 187–220.
Colonna, M, Hédelin, G, Estève, J, Grosclaude, P, Launoy, G, Buemi, A, Arveux, P, Tretarre, B, Chaplain, G, Lesec’h,, Raverdy, N, Carli, PM, Menegoz, F & Faivre, J National cancer prevalence estimation in France. Int J Cancer, (2000). 87, 301–304.
Spiers, ASD, Parekh, SJ & Bishop, MB Hairy cell leukemia: induction of complete remission with pentostatine (2-deoxycoformycin). J Clin Oncol, (1984). 2, 1336–1342.
Kraut, EH, Bouroncle, BA & Grever, MR Pentostatine in the treatment of advanced hairy cell leukemia. J Clin Oncol, (1989). 7, 168–172.
Finn, IW, Kopecky, KJ, Foucar, MK, Head, D, Bennett, JM, Hutchison, R, Corbett, W, Cassileth, P, Habermann, T, Golomb, H, Rai, K, Eisenhauer, E, Appelbaum, F, Cheson, B & Grever, MR Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood, (2000). 96, 2981–2986.
Saven, A, Burian, C, Koziol, JA & Piro, LD Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood, (1998). 92, 1918–1926.
Hakimian, D, Tallman, S, Hogan, DK, Rademaker, AW, Rose, E & Nemcek, AA Prospective evaluation on internal adenopathy in a cohort of 43 patients with hairy cell leukemia. J Clin Oncol, (1994). 12, 268–272.
Kurzrock, R, Strom, SS, Estey, E, O’Brien, S, Keating, MJ, Jiang, H, Adams, T & Talpaz, M Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol, (1997). 15, 1803–1810.
Seymour, JF, Talpaz, M & Kurzrock, R Response duration and recovery of CD4+ lymphocytes following deoxycoformycin ininterferon-α-resistant hairy cell leukemia: 7-year follow-up. Leukemia, (1997). 11, 42–47.
Golomb, HM, Dodge, R, Mick, R, Budman, D, Hutchinson, R, Horning, SJ & Schiffer, CA Pentostatin treatment for hairy cell leukemia who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia, (1994). 8, 2037–2040.
Saven, A, Burian, C, Adusumalli, J & Koziol, J Filgranstim for cladribine-induced neutropenia fever in patients with hairy cell leukemia. Blood, (1999). 93, 2471–2477.
Cheson, BD, Sorensen, JM, Vena, DA, Montello, MJ, Barrett, JA, Damasio, E, Tallman, M, Annino, L, Connors, J, Coiffier, B & Lauria, F Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the national Cancer Institute: a report of 979 patients. J Clin Oncol, (1998). 16, 3007–3015.
Federico, M, Zinzani, PL, Frassoldati, A, Vinceti, M, Modè, A, Annino, L, Chisesi, T, Pagnucco, G, Invernizzi, R, Spriano, M, Resegotti, L, Bendandi, M & Damassio, EE Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol, (2002). 20, 638–646.
Au, WY, Klasa, RJ, Gallagher, R, Le, N, Gascoyne, RD & Connors, JM Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood, (1998). 92, 1160–1164.
Cheson, BD Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol, (1995). 13, 2431–2448.
Kreitman, RJ, Wilson, WH, Bergeron, K, Raggio, M, Stetler-Stevenson, M, Fitzgerald, DJ & Pastan, I Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med, (2001). 345, 241–247.
Hagberg, H & Lundholm, L Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. Br J Haematol, (2001). 115, 609–611.
Acknowledgements
The following institutions (with main investigators) participated in the study: Hopital de l’Hotel-Dieu, Paris (Chauvenet L); Centre Hospitalier de Chalon s/Saone (Salles B, Baudet-Klepping S); Centre Hospitalier de Troyes (Dines G, Brahimi S); Centre Hospitalier du Nord Mayenne (Duquesnel F); Centre Hospitalier de Lorient (Moreau Ph); Centre Hospitalier d'Alençon (Frenkiel N); Hopital Percy Paris (Nedelec G, De Revel T); Centre Hospitalier de Colmar (Kohser F); HIA St Anne Toulon (de Jaureguiberry JP); Hopital ND du Bon Secours Metz (Christian B); Centre Hospitalier Le Mans (Dugay J); Centre Hospitalier Blois (Rodon Ph); Hopital Pontchalliou Rennes (Dauriac C); Centre Hospitalier Mulhouse (Eisenmann JC); Hopital Purpan Toulouse (Gaches F, Arlet-Suau E); CHU Lille (Noel MP, Bauters F); Clinique C Bernard Albi (Gaspard); Centre Hospitalier Béziers (David S); Centre Hospitalier Carcassonne (Vives JF); CHU Grenoble (Pegourie B); CHU Poitiers (Desmaret MC, Guilhot F); Hopital St Antoine Paris (Cheron N, Najman A); CHU Montpellier (Legouffe E); Hopital Purpan Toulouse (Schlaifer D, Payen C). We are indebted to Mrs Susan Dale who edited the manuscript and to I Cimarrosti who performed statistical analysis. This work was supported by a grant from Jansen-Cilag, France.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maloisel, F., Benboubker, L., Gardembas, M. et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 17, 45–51 (2003). https://doi.org/10.1038/sj.leu.2402784
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402784
Keywords
This article is cited by
-
Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances
Current Oncology Reports (2022)
-
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up
Blood Cancer Journal (2020)
-
Retrospective Analysis of Hairy Cell Leukemia Patients Treated with Different Modalities as First Line: Real-Life Experience Over 20 years
Indian Journal of Hematology and Blood Transfusion (2019)
-
Audit of compliance with the British Committee for Standards in Haematology (BCSH) revised guidelines for the diagnosis and assessment of treatment response of hairy cell leukemia in University Hospital Galway
Irish Journal of Medical Science (1971 -) (2017)
-
Hairy cell leukemia: short review, today’s recommendations and outlook
Blood Cancer Journal (2014)